一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括BH-30643；BH-30643 combo therapy with Carboplatin/Pemetrexed，当前状态为招募中。登记地点显示中国Phoenix、Irvine、La Jolla、Sacramento等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BH-30643；BH-30643 combo therapy with Carboplatin/Pemetrexed · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Mayo Clinic Hospital - Arizona · Phoenix
- The Regents of the University of California - Irvine, CA Campus · Irvine
- UC San Diego Moores Cancer Center · La Jolla
- University of California, Davis Comprehensive Cancer Center · Sacramento
- Stanford University Medical Center · Stanford
- Yale University - Cancer Center · New Haven
- Georgetown University Medical Center · Washington D.C.
- Mayo Clinic - Florida · Jacksonville
- Sarah Cancer Research Institution - Florida Cancer Specialist · Orlando
- Moffitt Cancer Center · Tampa
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion · Chicago
- Massachusetts General Hospital · Boston
- Beth Israel Deaconess Medical Center · Boston
- Dana-Farber Cancer Institute · Boston
- Henry Ford Health · Detroit
- Mayo Clinic Hospital - Rochester, MN · Rochester
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York
- Memorial Sloan Kettering Cancer Center · New York
- Duke Cancer Institute · Durham
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia
- Sarah Cannon Research Institute, LLC · Nashville
- The University of Texas - M.D. Anderson Cancer Center · Houston
- NEXT Virginia · Fairfax
- Fred Hutchinson Cancer Center · Seattle
- Austin Health · Heidelberg
- Peter MacCallum Cancer Centre · Melbourne
- Cross Cancer Institute · Edmonton
- Princess Margaret Cancer Centre · Toronto
- Prince of Wales Hospital · Shatin
- Queen Mary Hospital · Hong Kong
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * ≥ 18 years or legal adult.
- * Pathologically confirmed diagnosis of locally advanced or metastatic NSCLC with EGFR or HER2 mutations in the kinase domain of exons 18, 19, 20, or 21.
- * Has at least 1 measurable target extracranial lesion according to RECIST v1.1.
- * Eastern Cooperative Oncology Group Performance Status ≤ 1.
- * Has a life expectancy of ≥ 3 months.
- * Has adequate hematologic, hepatic, and renal function.
- The above are a summary; other Inclusion Criteria details may apply.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06706076；登记信息更新于 2026-08-05；本站同步于 2026-10-08。